ImmuneOncia Therapeutics, Inc. - Balance (Quarterly)

ImmuneOncia Therapeutics, Inc.
KR ˙ KOSDAQ
4.490,00 ₩ ↑65,00 (1,47%)
2026-06-05
DEL PRIS
Balance (Quarterly)

ImmuneOncia Therapeutics, Inc. Balance viser kontosaldi for virksomheden på tidspunkter. Balancedata inkluderer aktiver, omsætningsaktiver, anlægsaktiver, materielle anlægsaktiver (PPE), inventar, immaterielle aktiver, passiver, kortfristede forpligtelser, gæld, kapitalleasingforpligtelser, almindelige aktier, overført overskud, egne aktier og egenkapital.

Alle tal er gange 1,000,000.00 undtagen pr. andel enheder.

2021
12-31
2022
12-31
2023
12-31
2024
12-31
2025
06-30
2025
09-30
2025
12-31
2026
03-31
Kontanter 36.320 26.730 20.957 8.226 28.495 16.559 8.238 8.894
Ændring (%) -26,40 -21,60 -60,75 246,39 -41,89 -50,25 7,97
Aktiver Nuværende 42.667 28.970 26.636 19.863 45.647 36.063 26.506 21.057
Ændring (%) -32,10 -8,06 -25,43 129,81 -21,00 -26,50 -20,56
Aktiver 51.101 35.693 33.795 26.195 51.906 42.639 33.146 27.550
Ændring (%) -30,15 -5,32 -22,49 98,15 -17,85 -22,26 -16,88
Forpligtelser 110.633 88.100 3.710 6.771 4.400 4.843 4.730 4.435
Ændring (%) -20,37 -95,79 82,52 -35,01 10,06 -2,33 -6,25
Egenkapital -59.532 -52.407 30.086 19.424 47.505 37.796 28.415 23.115
Ændring (%) -11,97 -157,41 -35,44 144,57 -20,44 -24,82 -18,65
Passiver og Aktiekapital 51.101 35.693 33.795 26.195 51.906 42.639 33.146 27.550
Ændring (%) -30,15 -5,32 -22,49 98,15 -17,85 -22,26 -16,88

Source: Capital IQ

How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista